AnalystsBill Maughan
Bill Maughan's Stock Forecasts

Sectors:
Industries:
Analyst Ranking
Bottom 8%
#4946 out of 5342 analysts
Average Return
-10.31%
Win Rate
26%5 out of 19
Risk vs Reward
Poor
Good

Bill Maughan's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Dianthus Therapeutics IncDNTH
+175.00%$38.88$106.92
2025-09-17 -
2026-07-31
Strong Buy
Krystal Biotech IncKRYS
+167.37%$139.01$371.67
2025-07-01 -
2026-06-30
Strong Buy
Merus NvMRUS
+129.26%$21.94$50.30
2023-11-02 -
2024-11-01
Strong Buy
Annexon IncANNX
+25.49%$4.06$5.10
2025-12-02 -
2026-07-31
Strong Buy
Dianthus Therapeutics IncDNTH
+23.01%$86.92$106.92
2026-03-10 -
2026-07-31
Strong Buy

Bill Maughan Analyst Color

Get additional color on Bill Maughan's coverage of popular stocks

Bill Maughan's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Dianthus Therapeutics IncDNTH
2Strong Buy$130.00+21.59%Maintains
5 months ago
Ocular Therapeutix IncOCUL
1Strong Buy$28.00+242.72%Maintains
5 months ago
Korro Bio IncKRRO
2Strong Buy$18.00+73.58%Upgrades
5 months ago
Caribou Biosciences IncCRBU
1Strong Buy$13.00+790.41%Initiates Coverage On
6 months ago
Cellectis SaCLLS
1Strong Buy$9.00+227.27%Initiates Coverage On
7 months ago
Wave Life Sciences LtdWVE
2Strong Buy$47.00+752.99%Maintains
8 months ago
Annexon IncANNX
1Strong Buy$17.00+233.66%Initiates Coverage On
8 months ago
Y Mabs Therapeutics IncYMAB
3Hold$8.60-0.12%Downgrades
a year ago
Krystal Biotech IncKRYS
1Strong Buy$190.00N/AInitiates Coverage On
a year ago
Crispr Therapeutics AgCRSP
1Hold$45.00N/ADowngrades
a year ago
Nkarta IncNKTX
2Strong Buy$15.00N/AMaintains
2 years ago
Fate Therapeutics IncFATE
1Strong Buy$9.00N/AMaintains
2 years ago
Immunocore Holdings PLCIMCR
3Hold$67.00N/AMaintains
2 years ago
Moderna IncMRNA
3Hold$106.00N/AMaintains
2 years ago
Century Therapeutics IncIPSC
1Strong Buy$24.00N/AMaintains
2 years ago
Bicycle Therapeutics PLCBCYC
1Strong Buy$60.00N/AReiterates
2 years ago
Merus NvMRUS
1Strong Buy$45.00N/AInitiates Coverage On
3 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.